Indegene Limited has informed the Exchange about Investor Presentation
INDGN · price
▲ positive · ▼ negative · ● neutral filings · teal = economic event · numbered = multiple that day (click to pick). Times IST.
Awaiting price reaction for this filing.
Indegene Limited shared its investor presentation and fact sheet for Q4 FY25 and full year FY25 ended March 31, 2025. Q4 revenue grew 12.3% YoY to INR 7,556 Mn, with PAT at INR 1,176 Mn (15.6% margin, highest ever for any quarter). Full year FY25 revenue stood at INR 28,393 Mn (up 9.6% YoY), with PAT of INR 4,067 Mn (up 20.8% YoY) and EBITDA margin of 19.8%. The company has 73 active clients, with 66% of revenue from top 20 global biopharma firms, and announced its maiden 100% dividend. Management also launched Cortex, a GenAI platform for life sciences, and hosted an Investor Day on March 24 attended by 75+ analysts.
Strong quarterly performance with record PAT margin and robust cash position of INR 16,643 Mn signals healthy fundamentals for shareholders. Maiden dividend announcement and positive management commentary on deal wins and FY26 growth outlook should support investor confidence.